Juan Carlos Tinoco
Juan Carlos Tinoco has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Guzman-Holst
GSK, London, UK
2 shared publications - Gloria C. Huerta García
GSK México, Torre Mitikah Piso 19 y 20, Circuito Interior Avenida Río Churubusco 601, Col. Xoco. Alc. Benito Juárez, Mexico City 03330, Mexico
2 shared publications - Maria Yolanda Cervantes-Apolinar
GSK México, Torre Mitikah Piso 19 y 20, Circuito Interior Avenida Río Churubusco 601, Col. Xoco. Alc. Benito Juárez, Mexico City 03330, Mexico
2 shared publications - Abiel Homero Mascareñas-De Los Santos
Department of Pediatrics, Infectious Diseases Service, Universidad Autónoma de Nuevo León. Hospital Universitario “Dr. José Eleuterio González”, Monterrey, Nuevo León, Mexico
1 shared publication Agnes Akawung
Keyrus Life Science C/O GSK, Wavre, Belgium
1 shared publication- Alejandro Ernesto Macías
Department of Medicine and Nutrition, University of Guanajuato, León, Guanajuato, Mexico
1 shared publication
Latest Publications
- Open Access
- 9 July 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1803418
Pneumococcal community-acquired pneumonia in hospitalized adults in México 2018–2021: serotype distribution and clinical characteristics
Background: Community-acquired pneumonia (CAP) in adults represents a significant burden on the healthcare system in México, particularly among high-risk groups. Materials and methods: Adults hospitalized with chest X-ray-confirmed CAP (2018–2021) were prospectively enrolled across four cities in México (Mexico City, Durango, Mérida, and Tijuana). Urine samples were screened for Streptococcus pneumoniae ( S. pneumoniae ) using the BinaxNOW ® test and serotype-specific urine antigen detection (ssUAD) assays targeting 24 serotypes, and blood was obtained for pneumococcal culture. Results: Of the 1,275 patients screened for CAP, 389 had clinically or radiologically confirmed CAP (65.3% male; median age, 60 years; 39.3% aged ≥65 years). Pneumococcal CAP (pCAP) was identified in 12.1% of patients (47/389; 95% CI: 9.01–15.74). Based on CRB-65 scores, pCAP was more frequent among high-risk CAP patients (25.5%, 12/47) than among low- or moderate-risk CAP patients (10.2%, 35/342). Nevertheless, the 30-day mortality rate was 34.0% among pCAP patients versus 29.5% among S. pneumoniae -negative CAP patients. The most prevalent serotypes were 3 (13.0%), 6A (8.7%), and 19A (8.7%), and PCV20 would have covered 54.3% (25/46) of pCAP serotypes identified in this study. Conclusion: During the study period, CAP was associated with a substantial mortality burden among hospitalized adult patients in México, with pCAP more frequent among high-risk patients. These findings underscore the needs for enhanced diagnostic approaches and risk group-targeted adult pneumococcal vaccination programs.
- 9 July 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1803418
Open AccessPneumococcal community-acquired pneumonia in hospitalized adults in México 2018–2021: serotype distribution and clinical characteristics
Background: Community-acquired pneumonia (CAP) in adults represents a significant burden on the healthcare system in México, particularly among high-risk groups. Materials and methods: Adults hospitalized with chest X-ray-confirmed CAP (2018–2021) were prospectively enrolled across four cities in México (Mexico City, Durango, Mérida, and Tijuana). Urine samples were screened for Streptococcus pneumoniae ( S. pneumoniae ) using the BinaxNOW ® test and serotype-specific urine antigen detection (ssUAD) assays targeting 24 serotypes, and blood was obtained for pneumococcal culture. Results: Of the 1,275 patients screened for CAP, 389 had clinically or radiologically confirmed CAP (65.3% male; median age, 60 years; 39.3% aged ≥65 years). Pneumococcal CAP (pCAP) was identified in 12.1% of patients (47/389; 95% CI: 9.01–15.74). Based on CRB-65 scores, pCAP was more frequent among high-risk CAP patients (25.5%, 12/47) than among low- or moderate-risk CAP patients (10.2%, 35/342). Nevertheless, the 30-day mortality rate was 34.0% among pCAP patients versus 29.5% among S. pneumoniae -negative CAP patients. The most prevalent serotypes were 3 (13.0%), 6A (8.7%), and 19A (8.7%), and PCV20 would have covered 54.3% (25/46) of pCAP serotypes identified in this study. Conclusion: During the study period, CAP was associated with a substantial mortality burden among hospitalized adult patients in México, with pCAP more frequent among high-risk patients. These findings underscore the needs for enhanced diagnostic approaches and risk group-targeted adult pneumococcal vaccination programs.
- Open Access
- 14 January 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
A multicountry study to establish rates for pregnancy and neonatal outcomes in low- and middle-income regions
Background: Maternal vaccines can reduce the burden of diseases for both mother and neonate. The development and implementation of such vaccines require a thorough interpretation of safety data and standardized disease case definitions. This study aimed to evaluate the current rates for adverse pregnancy outcomes, maternal and neonatal events of interest (EOIs) that will be informative for preparing future phase III clinical trials on maternal vaccines conducted in low- and middle-income countries and further assisting in safety data interpretation (e.g., monitoring potential safety signals in clinical trials, and/or helping with the causality assessments of adverse events following immunization). Methods: We performed a prospective cohort study on healthy 18–45-year-old women, with singleton, low-risk pregnancies, with a gestational age of ≥24 0/7 weeks at enrollment and ≤27 6/7 weeks at first visit, and their neonates. The study was conducted between 2019–2021 in 10 countries that were considered low- and middle-income countries by the World Bank Group at the time the study was designed. All pregnancy-related outcomes and maternal EOIs occurring from enrollment up to 42 days post-delivery and neonatal EOIs occurring within the first 28 days after birth were recorded. Results: Of 2311 pregnant women and 2181 neonates enrolled, 2222 and 2094 were included in the analyses, respectively. Most livebirths (2088 [94.0%]) were without apparent congenital anomalies. Preterm delivery (166 [7.5%]), non-reassuring fetal status (137 [6.2%]), and hypertensive disorders of pregnancy (125 [5.6%]) were the most frequently reported EOIs related to pregnancy. The most frequent neonatal EOIs were low birthweight (including very low birthweight) (156 [7.4%]), preterm birth (141 [6.7%]), small for gestational age (111 [5.3%]), and congenital anomalies (103 [4.9%], including mainly major external structural defects, as well as detected internal and functional defects). Overall, there were similar frequencies in pregnancy outcomes, pregnancy-related and neonatal EOIs across countries, although some variation in the reporting rate was noted. Conclusion: This multicountry study contributes to establishing the most recent background rates for pregnancy outcomes, maternal and neonatal EOIs in low- and middle-income regions. The clinical relevance in the context of the safety assessment in future trials will be applied. Trial registration: NCT03614676 (03/08/2018).
- 14 January 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Open AccessA multicountry study to establish rates for pregnancy and neonatal outcomes in low- and middle-income regions
Background: Maternal vaccines can reduce the burden of diseases for both mother and neonate. The development and implementation of such vaccines require a thorough interpretation of safety data and standardized disease case definitions. This study aimed to evaluate the current rates for adverse pregnancy outcomes, maternal and neonatal events of interest (EOIs) that will be informative for preparing future phase III clinical trials on maternal vaccines conducted in low- and middle-income countries and further assisting in safety data interpretation (e.g., monitoring potential safety signals in clinical trials, and/or helping with the causality assessments of adverse events following immunization). Methods: We performed a prospective cohort study on healthy 18–45-year-old women, with singleton, low-risk pregnancies, with a gestational age of ≥24 0/7 weeks at enrollment and ≤27 6/7 weeks at first visit, and their neonates. The study was conducted between 2019–2021 in 10 countries that were considered low- and middle-income countries by the World Bank Group at the time the study was designed. All pregnancy-related outcomes and maternal EOIs occurring from enrollment up to 42 days post-delivery and neonatal EOIs occurring within the first 28 days after birth were recorded. Results: Of 2311 pregnant women and 2181 neonates enrolled, 2222 and 2094 were included in the analyses, respectively. Most livebirths (2088 [94.0%]) were without apparent congenital anomalies. Preterm delivery (166 [7.5%]), non-reassuring fetal status (137 [6.2%]), and hypertensive disorders of pregnancy (125 [5.6%]) were the most frequently reported EOIs related to pregnancy. The most frequent neonatal EOIs were low birthweight (including very low birthweight) (156 [7.4%]), preterm birth (141 [6.7%]), small for gestational age (111 [5.3%]), and congenital anomalies (103 [4.9%], including mainly major external structural defects, as well as detected internal and functional defects). Overall, there were similar frequencies in pregnancy outcomes, pregnancy-related and neonatal EOIs across countries, although some variation in the reporting rate was noted. Conclusion: This multicountry study contributes to establishing the most recent background rates for pregnancy outcomes, maternal and neonatal EOIs in low- and middle-income regions. The clinical relevance in the context of the safety assessment in future trials will be applied. Trial registration: NCT03614676 (03/08/2018).
- Open Access
- 6 November 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (1) , 103030
Pneumococcal meningitis in Mexico. Serotype distribution and antimicrobial resistance before and after the introduction of pneumococcal conjugate vaccines in pediatric patients. Results from the GIVEBPVac group
- 6 November 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (1) , 103030
Open AccessPneumococcal meningitis in Mexico. Serotype distribution and antimicrobial resistance before and after the introduction of pneumococcal conjugate vaccines in pediatric patients. Results from the GIVEBPVac group
- Open Access
Challenges and Opportunities for Adult Vaccine Coverage: Insights for Healthcare Professionals Focusing on Herpes Zoster in Mexico
Herpes zoster (HZ) is a common disease in older adults and immunocompromised patients, and is frequently associated with long-term complications that impact quality of life. Fortunately, more than one vaccine against HZ is now available in Mexico. Two expert consensus groups discussed adult vaccination strategies in Mexico, focusing on HZ in older adults and immunocompromised individuals; their insights are reported here. HZ is usually treated inappropriately in Mexico. Late diagnosis and suboptimal management are common, as is a lack of treatment options, particularly for pain, which is often unresponsive to standard painkillers. Improving vaccination rates against HZ in Mexico is therefore important, but several barriers to HZ vaccination exist. It is not included in the national vaccination schedule, where included vaccines usually have higher coverage. Actions to overcome barriers include improving awareness of HZ and vaccine availability, developing and promoting guidelines and recommendations for vaccination, and expanding access and infrastructure for vaccination.
Open AccessChallenges and Opportunities for Adult Vaccine Coverage: Insights for Healthcare Professionals Focusing on Herpes Zoster in Mexico
Herpes zoster (HZ) is a common disease in older adults and immunocompromised patients, and is frequently associated with long-term complications that impact quality of life. Fortunately, more than one vaccine against HZ is now available in Mexico. Two expert consensus groups discussed adult vaccination strategies in Mexico, focusing on HZ in older adults and immunocompromised individuals; their insights are reported here. HZ is usually treated inappropriately in Mexico. Late diagnosis and suboptimal management are common, as is a lack of treatment options, particularly for pain, which is often unresponsive to standard painkillers. Improving vaccination rates against HZ in Mexico is therefore important, but several barriers to HZ vaccination exist. It is not included in the national vaccination schedule, where included vaccines usually have higher coverage. Actions to overcome barriers include improving awareness of HZ and vaccine availability, developing and promoting guidelines and recommendations for vaccination, and expanding access and infrastructure for vaccination.
- Open Access
- 8 November 2022
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 12 (1) , 131-141
Epidemiology of Herpes Zoster in Adults in Mexico: A Retrospective Database Analysis
Introduction The risk of herpes zoster (HZ) increases with age. In countries with an ageing population such as Mexico, a rise in the risk of HZ and complications is expected. The goal of this study was to provide an updated estimate of the potential burden of HZ and associated complications in Mexico. Methods A retrospective database study was performed using data from the national surveillance database of the Ministry of Health (Secretaría de Salubridad y Asistencia/Dirección General de Información en Salud). HZ cases and associated complications were identified via the International Classification of Diseases 10th Revision codes. Emergency room (ER) visits, hospitalizations, and deaths were extracted and analyzed by age group and year. The observation period was between 2011 and 2020 for ER visits and hospitalizations and between 2011 and 2019 for deaths. Cumulative incidence per 1000 people and case fatality rate were estimated. Results During the observation period, 53,030 ER visits, 4172 hospitalizations, and 263 deaths due to HZ were reported nationwide. The cumulative incidence of HZ based on ER visits was 1.04 per 1000 people aged ≥ 50 years but increased in older age groups (1.47 per 1000 people aged ≥ 65 years). The most common complications were neuralgia (10.9%), ocular disease (7.0%), meningoencephalitis (2.9%), and disseminated disease (3.1%). Patients ≥ 65 years accounted for 37% of hospitalizations and 81% of deaths. Conclusion In Mexico, HZ and its complications impose a considerable burden on the population and the healthcare system. Prospective surveillance studies are required to obtain an accurate picture of the current epidemiology of HZ in Mexico and to estimate the benefits of future vaccination strategies against HZ.
- 8 November 2022
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 12 (1) , 131-141
Open AccessEpidemiology of Herpes Zoster in Adults in Mexico: A Retrospective Database Analysis
Introduction The risk of herpes zoster (HZ) increases with age. In countries with an ageing population such as Mexico, a rise in the risk of HZ and complications is expected. The goal of this study was to provide an updated estimate of the potential burden of HZ and associated complications in Mexico. Methods A retrospective database study was performed using data from the national surveillance database of the Ministry of Health (Secretaría de Salubridad y Asistencia/Dirección General de Información en Salud). HZ cases and associated complications were identified via the International Classification of Diseases 10th Revision codes. Emergency room (ER) visits, hospitalizations, and deaths were extracted and analyzed by age group and year. The observation period was between 2011 and 2020 for ER visits and hospitalizations and between 2011 and 2019 for deaths. Cumulative incidence per 1000 people and case fatality rate were estimated. Results During the observation period, 53,030 ER visits, 4172 hospitalizations, and 263 deaths due to HZ were reported nationwide. The cumulative incidence of HZ based on ER visits was 1.04 per 1000 people aged ≥ 50 years but increased in older age groups (1.47 per 1000 people aged ≥ 65 years). The most common complications were neuralgia (10.9%), ocular disease (7.0%), meningoencephalitis (2.9%), and disseminated disease (3.1%). Patients ≥ 65 years accounted for 37% of hospitalizations and 81% of deaths. Conclusion In Mexico, HZ and its complications impose a considerable burden on the population and the healthcare system. Prospective surveillance studies are required to obtain an accurate picture of the current epidemiology of HZ in Mexico and to estimate the benefits of future vaccination strategies against HZ.